Back to top
more

Incyte (INCY)

(Delayed Data from NSDQ)

$57.05 USD

57.05
3,395,231

0.00 (0.00%)

Updated May 15, 2024 04:00 PM ET

After-Market: $57.79 +0.74 (1.30%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Will Radius Health (RDUS) Disappoint This Earnings Season?

Radius Health (RDUS) has a disappointing track record and we expect the trend to continue when it reports third-quarter results on Nov 2.

    Get Rid of These 5 Toxic Stocks or Sell Short for Profit

    Toxic stocks are vulnerable to outside shocks and are burdened with high amounts of debts. Also, the price of toxic stocks is inflated.

      Why Incyte (INCY) Might Surprise This Earnings Season

      Incyte (INCY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

        Is a Beat in Store for Alexion (ALXN) This Earnings Season?

        Alexion's (ALXN) blockbuster drug, Soliris, continues to perform well and the company is scheduled to report third-quarter 2017 results on Oct 26, before the opening bell.

          Lilly (LLY) Beats on Q3 Earnings, Explores Sale of Elanco

          Eli Lilly (LLY) beat estimates for both sales and earnings in Q3 and upped its 2017 outlook. Separately, the company said that it is exploring strategic alternatives for the Elanco Animal Health business.

            Eli Lilly (LLY) to Report Q3 Earnings: What's in Store?

            Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

              5 Toxic Stocks to Abandon or Sell Short for Gains

              Toxic stocks are susceptible to external shocks and are loaded with high amounts of debts. Also, the price of toxic stocks is irrationally high.

                Agenus (AGEN) Remains Focused on Drug Development Programs

                Agenus' (AGEN) collaboration agreements provide a steady source of funds to boost pipeline development.

                  J&J's Arthritis Candidate Sirukumab Denied FDA Approval

                  J&J (JNJ) said that the FDA has denied approval to its investigational rheumatoid arthritis treatment, sirukumab for want of additional safety data.

                    Zacks.com featured highlights: PTC, Apache, Incyte, Titan International and Carbonite

                    Zacks.com featured highlights: PTC, Apache, Incyte, Titan International and Carbonite

                      5 Toxic Stocks to Discard or Sell Short for Profit

                      Toxic stocks are exposed to outside shocks and are burdened with high levels of debts. Also, the price of toxic stocks is artificially inflated.

                        Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study

                        Eli Lilly and Company (LLY) and partner Incyte announced that baricitinib met its primary endpoint in a phase II study in people with moderate-to-severe atopic dermatitis.

                          Incyte (INCY) Reports Positive Data on Epacadostat/Keytruda

                          Incyte Corporation (INCY) announced new and updated data from the ongoing phase I/II ECHO-202 trial on pipeline candidate epacadostat with Keytruda.

                            Mark Vickery headshot

                            Top Research Reports for Bank of America, Pepsi & American Express

                            Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), American Express (AXP), and Pepsi (PEP).

                              Lilly/Incyte to Re-File Baricitinib NDA Faster Than Expected

                              Lilly (LLY) and Incyte announced that they will re-submit the new drug application (NDA) for their rheumatoid arthritis (RA) drug, baricitinib much faster than previously expected.

                                Incyte (INCY) Q2 Loss Wider than Expected, Jakafi Strong

                                Incyte (INCY) reported a wider-than-expected loss in the second quarter but revenues beat expectations.

                                  Arpita Dutt headshot

                                  Key Takeaways from Lilly's (LLY) Q2 Call: Baricitinib, Cancer Pipeline

                                  Why were Lilly's (LLY) shares down despite the company delivering a "beat and raise" quarter?

                                    Arpita Dutt headshot

                                    Biotech Stock Roundup: Amgen, Biogen Top Q2 Estimates, Update on Incyte RA Drug

                                    Earnings season kicked off on a positive note for biotech stocks with big players like Amgen (AMGN) and Biogen reporting better than expected results.

                                      Lilly (LLY) Q2 Earnings Top, Baricitinib Re-Filing Delayed

                                      Eli Lilly and Company (LLY) beat estimates for both sales and earnings in Q2 and upped its 2017 outlook. However, it said the NDA resubmission for baricitinib will not occur this year, which hurt shares.

                                        Incyte & Lilly's Olumiant Gets Marketing Approval in Japan

                                        Incyte Corporation (INCY) and partner Eli Lilly and Company (LLY) announced that arthritis drug Olumiant got approval in Japan.

                                          Aduro Starts Phase II Combo Study with CRS-207 & Keytruda

                                          Aduro Biotech, Inc. (ADRO) has announced initiation of a phase II study to evaluate a combination therapy of its lead candidate, CRS-207, in combination with Keytruda, for treatment of patients with pleural mesothelioma (MPM).

                                            Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca

                                            Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca

                                              Arpita Dutt headshot

                                              Better Days Ahead for the Pharma Sector?

                                              Sales, R&D, strong results, and a higher number of FDA approvals.

                                                Eric Dutram headshot

                                                Stocks to Fight Cancer: Why Immunotherapy Is a Gamechanger

                                                This podcast takes a closer look at the world of cancer research, and in particular, that of immunotherapy. I have guest Brad Loncar on to discuss this market and a few promising candidates to watch in this area, check it out for more info on this interesting biotech segment!

                                                  Incyte (INCY) Up 3.4% Since Earnings Report: Can It Continue?

                                                  Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.